| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,928 | 3,952 | 28.01. | |
| 3,920 | 3,948 | 28.01. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 20,000 | 400 | |||
| 12,950 | 375 | |||
| 9,900 | 100 | |||
| 8,000 | 1.350 | |||
| 7,000 | 3.900 | |||
| 6,600 | 200 | |||
| 5,500 | 2.455 | |||
| 5,000 | 900 | |||
| 3,948 | 1.865 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/ayj.htm [/URL] | ||||
| 1.865 | 3,920 | |||
| 1.000 | 3,640 | |||
| 1.068 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.933 | 2,935 | 11.545 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:21:30 | 4,022 | 339 |
| 17:21:30 | 4,020 | 20 |
| 16:59:55 | 4,000 | 3 |
| 16:29:51 | 4,028 | 710 |
| 16:16:27 | 4,018 | 37 |
| 16:06:10 | 4,010 | 40 |
| 15:30:02 | 4,054 | 10 |
| 15:08:08 | 4,036 | 373 |
| 15:08:08 | 4,018 | 1 |
| 14:35:47 | 4,010 | 5.244 |
| 14:26:11 | 3,992 | 2 |
| 14:26:11 | 3,980 | 28 |
| 14:01:11 | 3,982 | 50 |
| 10:58:35 | 4,032 | 1.998 |
| 10:58:35 | 4,034 | 3.254 |
| 10:42:30 | 4,052 | 247 |
| 10:42:30 | 4,050 | 9 |
| 09:16:19 | 4,040 | 53 |
| 09:04:50 | 4,008 | 1 |
| Tagesumsatz Xetra | -0,074 -1,81 % | 26.397 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Abend-Update: Valneva auffällig ruhig - Ruhe vor dem Sturm? | Hebelschein-Spekulant | |||
| Mo | VALNEVA SE - Schwäche mit Signalcharakter | 79 | Maximilian Berger | ||
| VALNEVA Aktie jetzt für 0€ handeln | |||||
| 20.01. | Valneva Steps Back From US Approval Bid For Chikungunya Vaccine | 67 | Benzinga.com | ||
| 20.01. | Valneva to withdraw Chikungunya vaccine from US amid safety woes | 58 | BioPharma Dive | ||
| 20.01. | Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation | 51 | FiercePharma |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain | ACCESS Newswire | ~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")... ► Artikel lesen | |
| Mi | BioNTech ernennt Kylie Jimenez zur Chief People Officer | 4investors | Der Aufsichtsrat der BioNTech SE hat Kylie Jimenez mit Wirkung zum 1. März 2026 zur neuen Chief People Officer (Chief People Officer) ernannt. Die neu geschaffene Vorstandsposition umfasst die Verantwortung... ► Artikel lesen | |
| Mi | NurExone ebnet den Weg für klinischen Start von ExoPTEN | Small- & Micro Cap Investment | ||
| Mi | Morning Market Movers: Murano Global Investments, Flora Growth, Kustom Entertainment, Ainos See Big Swings | AFX News | OTTAWA (dpa-AFX) - At 7:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 00:24 | GenSight Biologics S.A.: GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 | Business Wire | Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal... ► Artikel lesen |